SEC Comment Letter for Viskase Holdings, (VISK) — Nov 17, 2020
Viskase Holdings, Inc.
Date: Nov. 17, 2020 · CIK: 0000727510 · Accession: 0000000000-20-011021
AI Filing Summary & Sentiment
File numbers found in text: 333-250031
Letter
United States securities and exchange commission logo November 17, 2020 Andrew Rackear Chief Executive Officer and Secretary Enzon Pharmaceuticals, Inc. 20 Commerce Drive (Suite 135) Cranford, NJ 07016 Re:Enzon Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed November 12, 2020 File No. 333-250031 Dear Mr. Rackear: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact David Gessert at 202-551-2326 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
November 17, 2020
Andrew Rackear
Chief Executive Officer and Secretary
Enzon Pharmaceuticals, Inc.
20 Commerce Drive (Suite 135)
Cranford, NJ 07016
Re:Enzon Pharmaceuticals, Inc.
Registration Statement on Form S-1
Filed November 12, 2020
File No. 333-250031
Dear Mr. Rackear:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact David Gessert at 202-551-2326 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences